Skip to main content

Table 2 Clinical characteristics of VKH patients

From: Outcomes of retinal pigment epithelial detachment in Vogt-Koyanagi-Harada disease: a longitudinal analysis

Case

Age / Gender

Eye

BCVA at baseline

BCVA at final visit

Follow up (months)

The time of PED occurrence

PEDA (degree)

CSC occurrence

Time between PED and CSC

PED outcomes

Treatment

1

46 / F

OD

20/50

20/20

10

Initial visist

109.80

No

-

Regression

Routine oral steroid tapering

2

49 / F

OD

20/200

20/20

13

Initial visist

101.82

No

-

Regression

Routine oral steroid tapering & AZA

3

34 / F

OD

20/63

20/20

12

Initial visit

112.93

No

-

Regression

Routine oral steroid tapering

OS

20/63

20/20

12

Initial visit

63.61

No

-

Regression

Routine oral steroid tapering

4

60 / F

OS

20/40

20/33

7

Initial visit

133.87

No

-

Regression

Routine oral steroid tapering

5

(Fig. 2)

40 / M

OS

20/200

20/20

10

Initial visit

83.18

Yes

3 months

Persistence

Rapid oral steroid tapering & MMF subthreshold micropulse laser photocoagulation & continue-wave laser photocoagulation

6

30 / F

OD

20/40

20/40

18

During follow-up

89.60

Yes

6 months

Regression

Rapid oral steroid tapering & CsA & AZA & subthreshold micropulse laser photocoagulation

7

58 / F

OD

20/2000

0.2

6

Initial visit

125.73

No

-

Regression

Intravenous methylprednisolone & oral tapering steroid & CsA

8

62 / M

OS

20/22

20/20

6

During follow-up

100.33

No

-

Regression

Oral tapering steroid

9

64 / M

OD

20/200

20/28

9

Initial visit

59.92

Yes

2 months

Regression

Rapid oral steroid tapering & MMF

10 (Fig. 3)

47 / F

OD

20/33

20/63

8

Initial visit

78.89

Yes

0

Regression

Rapid oral steroid tapering off & CsA & MMF & ADA & subthreshold micropulse laser photocoagulation

 

OS

20/40

20/63

8

Initial visit

76.88

Yes

0

Regression

Rapid oral steroid tapering off & CsA & MMF & ADA & subthreshold micropulse laser photocoagulation

  1. F Female, M Male, PED Retinal pigment epithelial detachment, PEDA PED angle; CSC, central serous chorioretinopathy, AZA Azathioprine, CsA Ciclosporin A, ADA Adalimumab, MMF Mycophenolate mofetil